Receptor News and Research

RSS

Researchers develop a multivalent vaccine for COVID-19 and influenza

Researchers at Duke University, USA, are looking into the possibility of a combined influenza and COVID-19 vaccine that could be used to simultaneously protect against annual flu strains and the SARS-CoV-2. Preclinical results showed the vaccine protected mice from both SARS-CoV-2 and the flu.

6 May 2021

Study finds no evidence of increased risk for COVID-19 from aspirin/NSAID use

At the beginning of the pandemic, there were concerns over the use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs), increasing the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. NSAIDs are commonly used to treat SARS-CoV-2 infection-related symptoms such as flu and cough and are frequently taken by older adults with multiple health conditions.

6 May 2021

Monocytes promote viral control during SARS-COV-2 infection

In a paper recently uploaded to the preprint server bioRxiv by Vanderheiden et al. (May 4th, 2021) the contribution of monocytes in promoting protective immunity from SARS-CoV-2 is investigated in a murine model, suggesting that CCR2 plays the role of an inflammation modulator in early infection.

6 May 2021

Novel pipeline identifies millions of molecular targets in SARS-CoV-2

Researchers in the United States have developed a novel pipeline for high-throughput, automated annotation of the genes, proteins and functional domains in the genome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

5 May 2021

Prior MMR or Tdap vaccination may reduce risk of severe COVID-19

Researchers in the United States have shown that prior Measles-Mumps-Rubella (MMR) or Tetanus-Diphtheria-pertussis (Tdap) vaccination may reduce the risk of severe outcomes in patients with coronavirus disease 2019 (COVID-19).

5 May 2021

Nanoparticle (SpFN) vaccine candidate elicits multifactorial cellular immune responses against SARS-CoV-2 in vivo

Researchers have developed a promising new anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)vaccine candidate that utilizes nanotechnology and shows robust, long-lived immunity in mouse models.

5 May 2021

Mechano-immunological response to SARS-CoV-2

In a recent study, researchers demonstrated a human organ-on-a-chip (Organ Chip) microfluidic model of the lung alveolus (Alveolus Chip) - that recapitulates the human alveolar-capillary interface with an air-liquid interface (ALI) and vascular fluid flow to understand the local triggers in the lung in vitro.

5 May 2021

Immunome could provide unprecedented insight into an individual’s health

The human immune system doesn't just protect our health, it reflects it. Each encounter with a potential disease-causing agent causes the body to produce specific immune agents -- proteins known as antibodies and T-cell receptors -- tailor-made to recognize and destroy the invader.

5 May 2021

New combination treatment could benefit T-ALL patients who do not respond to chemotherapy

T-cell acute lymphoblastic leukemia is an aggressive cancer type that mostly affects children. The standard treatment is chemotherapy, but about one in four patients do not respond or develop resistance to this.

4 May 2021

Researchers identify mechanism of platelet hyperactivation in COVID-19 patients

A recent study conducted at the University of Pennsylvania and the Children’s Hospital of Philadelphia, USA, has revealed the mechanism of platelet hyperactivation in critically ill coronavirus disease 2019 (COVID-19) patients.

4 May 2021

What happens in the first few days of SARS-CoV-2 infection?

New research, published in PLOS Biology, has evaluated SARS-CoV-2 infection in primary cultures of well-differentiated cells to determine how the virus affects the body and how the infection starts. Answers to these questions are essential to forming a general understanding of viral pathogenesis, which helps us develop effective prevention and treatment strategies for COVID-19.

4 May 2021

Can SARS-CoV-2’s impairment of endothelium cause vascular disease?

The study, published in the journal Circulation Research, suggests that COVID-19 is not only a respiratory disease but also a vascular disease. It highlights how the virus attacks the vascular system, causing endothelial impairment.

4 May 2021

Could in vitro glycoengineering help produce better SARS-CoV-2 spike candidates for vaccine research?

A vexing problem in the development of vaccines has been the need to achieve the right glycosylation profile for the viral antigens. A new study, recently released as a preprint on the bioRxiv* server, shows how a sequential cell-free approach produced complex N-glycans from simpler types, in a one-pot reaction.

4 May 2021

Evidence that elevated blood glucose is a significant risk factor for severe COVID-19

The literature analysis pointed to elevated blood glucose levels as a leading facilitator in the progression of COVID-19. Evidence linking elevated glucose to various steps in the life cycle of the virus and presentation of COVID-19 symptoms were also found.

3 May 2021

SARS-CoV-2 study in human gut organoids

Most of the major life-threatening symptoms of COVID-19 disease are associated with the host's generation of an exacerbated pro-inflammatory immune response. Many studies have correlated the intensity of the immune response with the severity of disease.

3 May 2021

Differential NK cell activity found to contribute to SARS-CoV-2 infection resistance

The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected millions of people worldwide and is the leading cause of mortality in Brazil in 2020 as well as early 2021. Clinical manifestations of COVID-19 disease range from no symptoms and mild flu-like symptoms to severe cases leading to hospitalization and death.

3 May 2021

Monoclonal antibody neutralizes all SARS-CoV-2 variants of concern

Researchers in Canada and the United States have identified a monoclonal antibody that potently neutralizes variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the ongoing coronavirus disease 2019 (COVIdD-19) pandemic.

3 May 2021